---
title: "Abridge revenue and valuation"
description: "Abridge's ARR is estimated at $136M–$360M, last reported at $117M. Valued at $5.3B after raising $780M. Funding rounds and competitors."
url: https://www.tryspecter.com/revenue-valuation/abridge.md
canonical_url: https://www.tryspecter.com/revenue-valuation/abridge
publisher: Specter
last_updated: 2026-11-01
---

# Abridge revenue and valuation

Specter estimates Abridge's annual revenue at $136M to $360M and its valuation at $4.75B to $6.64B. The company last reported $117M ARR in June 2025 and was priced at $5.3B in June 2025.

Abridge converts patient-clinician conversations into structured, billable clinical documentation.

- Estimated revenue: $136M to $360M (October 2026)
- Estimated valuation: $4.75B to $6.64B (October 2026)
- Last reported ARR: $117M (June 2025)
- Total funding: $780M
- Founded: 2018
- Headquarters: San Francisco, United States
- Employees: 676
- Sector: Health AI
- Specter Rank: #81,283

## Abridge revenue

Abridge last reported $117M ARR in June 2025. Specter's model puts current ARR between $136M and $360M.

| Reported figure | Date | Source |
| --- | --- | --- |
| $117M ARR | June 2025 | [Medical AI startup Abridge closes $300M investment at $5.3B valuation](https://siliconangle.com/2025/06/24/medical-ai-startup-abridge-closes-300m-investment-5-3b-valuation/) (siliconangle.com) |

| Month | Specter estimate | Low | High |
| --- | --- | --- | --- |
| October 2026 | $220M | $136M | $360M |
| September 2026 | $195M | $127M | $300M |
| August 2026 | $198M | $134M | $290M |
| July 2026 | $193M | $129M | $290M |
| June 2026 | $186M | $126M | $270M |
| May 2026 | $160M | $99M | $260M |
| April 2026 | $153M | $96M | $240M |
| March 2026 | $150M | $97M | $230M |
| February 2026 | $147M | $95M | $230M |
| January 2026 | $146M | $98M | $220M |
| December 2025 | $137M | $91M | $200M |
| November 2025 | $135M | $96M | $190M |
| October 2025 | $132M | $96M | $182M |
| September 2025 | $129M | $94M | $176M |
| August 2025 | $129M | $99M | $167M |
| July 2025 | $124M | $99M | $155M |
| June 2025 | $117M | $97M | $141M |
| May 2025 | $52M | $23M | $81M |
| April 2025 | $48M | $21M | $75M |
| March 2025 | $48M | $16M | $81M |
| February 2025 | $42M | $14M | $71M |
| January 2025 | $34M | $13M | $55M |
| December 2024 | $31M | $11M | $51M |
| November 2024 | $26M | $10M | $42M |
| October 2024 | $26M | $10M | $42M |
| September 2024 | $19M | $6.7M | $32M |
| August 2024 | $30M | $6.7M | $52M |
| July 2024 | $21M | $4.3M | $38M |
| June 2024 | $15M | $6M | $25M |

## Abridge valuation

Abridge's valuation rose from $850M at its Series C in February 2024 to $5.3B at its Series E in June 2025. Specter's live estimate sits between $4.75B and $6.64B.

| Month | Specter estimate | Low | High |
| --- | --- | --- | --- |
| October 2026 | $5.62B | $4.75B | $6.64B |
| September 2026 | $5.1B | $3.7B | $7.03B |
| August 2026 | $5.08B | $3.85B | $6.71B |
| July 2026 | $5.07B | $3.98B | $6.44B |
| June 2026 | $5.14B | $4.18B | $6.33B |
| May 2026 | $5.3B | $4.41B | $6.37B |
| April 2026 | $5.3B | $3.92B | $7.16B |
| March 2026 | $5.3B | $4.13B | $6.8B |
| February 2026 | $5.3B | $4.2B | $6.69B |
| January 2026 | $5.3B | $4.31B | $6.52B |
| December 2025 | $5.3B | $4.37B | $6.42B |
| November 2025 | $5.3B | $4.41B | $6.37B |
| October 2025 | $5.3B | $4.31B | $6.51B |
| September 2025 | $5.3B | $4.37B | $6.42B |
| August 2025 | $5.3B | $4.41B | $6.37B |
| July 2025 | $5.3B | $4.41B | $6.37B |
| June 2025 | $5.3B | $4.41B | $6.37B |
| May 2025 | $4.5B | $3.59B | $5.64B |
| April 2025 | $3.82B | $3.11B | $4.68B |
| March 2025 | $3.24B | $2.67B | $3.93B |
| February 2025 | $2.75B | $2.29B | $3.31B |
| January 2025 | $2.99B | $2.17B | $4.11B |
| December 2024 | $3.24B | $2.39B | $4.4B |
| November 2024 | $3.52B | $2.55B | $4.85B |
| October 2024 | $3.82B | $2.85B | $5.12B |
| September 2024 | $4.14B | $3.11B | $5.52B |
| August 2024 | $4.5B | $3.52B | $5.75B |
| July 2024 | $4.88B | $3.98B | $5.99B |
| June 2024 | $5.3B | $4.41B | $6.37B |

| Reported valuation | Month | Source |
| --- | --- | --- |
| $5.3B | May 2026 | [cxodigitalpulse.com](https://www.cxodigitalpulse.com/healthcare-ai-startup-abridge-ceo-shares-leadership-advice-from-nvidias-jensen-huang/) |
| $5.3B | November 2025 | [business-review.eu](https://business-review.eu/br-exclusive/br-analysis-ai-spearheads-startup-valuations-as-unicorn-pipeline-slows-291438) |
| $5.3B | August 2025 | [linkedin.com](https://www.linkedin.com/posts/reena-sooch_dayone-ai-advisory-activity-7361412318116618241-dott) |
| $5.3B | July 2025 | [siliconangle.com](https://siliconangle.com/2025/06/24/medical-ai-startup-abridge-closes-300m-investment-5-3b-valuation/) |
| $5.3B | June 2025 | Funding round |
| $2.75B | February 2025 | Funding round |
| $5.3B | June 2024 | [techcrunch.com](https://www.techcrunch.com/latest/in-just-4-months-ai-medical-scribe-abridge-doubles-valuation-to-5-3b/) |
| $850M | February 2024 | Funding round |
| $5.3B | November 2023 | [techcrunch.com](https://www.techcrunch.com/in-brief/in-just-4-months-ai-medical-scribe-abridge-doubles-valuation-to-5-3b/) |

## Abridge funding rounds

| Date | Round | Raised | Post-money | Lead investors |
| --- | --- | --- | --- | --- |
| 11 Jun 2026 | Corporate round | Undisclosed | Undisclosed | Eli Lilly |
| 7 Jan 2026 | Venture round | $22.5M | Undisclosed | Undisclosed |
| 24 Jun 2025 | Series E | $300M | $5.3B | Andreessen Horowitz, Khosla Ventures |
| 17 Feb 2025 | Series D | $250M | $2.75B | IVP, Elad Gil |
| 23 Feb 2024 | Series C | $150M | $850M | Redpoint, Lightspeed Venture Partners |
| 26 Oct 2023 | Series B | $30M | Undisclosed | Spark Capital |
| 18 May 2023 | Corporate round | Undisclosed | Undisclosed | IKS Health |
| 11 Aug 2022 | Series A | $12.5M | Undisclosed | Wittington Ventures |
| 6 Oct 2020 | Series A | $10M | Undisclosed | Union Square Ventures, UPMC |
| 16 Jul 2019 | Seed | $5M | Undisclosed | Undisclosed |

## Abridge vs competitors

The AI medical scribe market pits broad clinical automation against specialized documentation workflows.

| Company | Estimated revenue | Estimated valuation |
| --- | --- | --- |
| Abridge | $136M–$360M | $4.75B–$6.64B |
| Ambience Healthcare (ambiencehealthcare.com) | $8.3M–$53M | $950M–$1.52B |
| Suki AI (suki.ai) | $26M–$173M | $1.04B–$1.13B |
| Augmedix (augmedix.com) | $11M–$87M | $68M–$440M |
| Heidi (heidihealth.com) | $55M–$85M | $810M–$1.16B |

## Questions

### What is Abridge's revenue?

Specter estimates Abridge's annual recurring revenue at $136M to $360M as of October 2026. Abridge last reported $117M ARR in June 2025.

### What is Abridge's valuation?

Abridge's latest post-money valuation is $5.3B, from a June 2025 Series E. Specter's live estimate is $4.75B to $6.64B.

### What is Abridge's revenue multiple?

Abridge is valued at about 45.3× ARR, based on its $5.3B June 2025 valuation and $117M last reported ARR.

### How much funding has Abridge raised?

$780M across 10 rounds, from a $5M Seed in July 2019 to a corporate round in June 2026.

### Who invested in Abridge?

35 investors, including Andreessen Horowitz, Elad Gil, Eli Lilly, IVP, Khosla Ventures and Redpoint.

### Who are Abridge's competitors?

Ambience Healthcare, Suki AI, Augmedix and Heidi. Specter ranks 30 competitors for Abridge.

## About this data

Specter models revenue and valuation monthly and anchors each estimate to reported figures and priced rounds. Method: https://www.tryspecter.com/revenue-valuation

Cite as: Specter. "Abridge revenue and valuation." tryspecter.com/revenue-valuation/abridge. Updated November 2026.